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Background: Superparamagnetic iron oxide nanoparticles are attractive materials that have 
been widely used in medicine for drug delivery, diagnostic imaging, and therapeutic applica-
tions. In our study, superparamagnetic iron oxide nanoparticles and the anticancer drug, doxo-
rubicin hydrochloride, were encapsulated into poly (D, L-lactic-co-glycolic acid) poly (ethylene 
glycol) (PLGA-PEG) nanoparticles for local treatment. The magnetic properties conferred by 
superparamagnetic iron oxide nanoparticles could help to maintain the nanoparticles in the 
joint with an external magnet.
Methods: A series of PLGA:PEG triblock copolymers were synthesized by ring-opening 
polymerization of D, L-lactide and glycolide with different molecular weights of polyethylene 
glycol (PEG2000, PEG3000, and PEG4000) as an initiator. The bulk properties of these c  opolymers 
were characterized using  1H nuclear magnetic resonance spectroscopy, gel permeation 
  chromatography, Fourier transform infrared spectroscopy, and differential scanning calorimetry. 
In addition, the resulting particles were characterized by x-ray powder diffraction, scanning 
electron microscopy, and vibrating sample magnetometry.
Results: The doxorubicin encapsulation amount was reduced for PLGA:PEG2000 and 
PLGA:PEG3000 triblock copolymers, but increased to a great extent for PLGA:PEG4000 triblock 
copolymer. This is due to the increased water uptake capacity of the blended triblock copolymer, 
which encapsulated more doxorubicin molecules into a swollen copolymer matrix. The drug 
encapsulation efficiency achieved for Fe3O4 magnetic nanoparticles modified with PLGA:PEG2000, 
PLGA:PEG3000, and PLGA:PEG4000 copolymers was 69.5%, 73%, and 78%, respectively, 
and the release kinetics were controlled. The in vitro cytotoxicity test showed that the Fe3O4-
PLGA:PEG4000 magnetic nanoparticles had no cytotoxicity and were biocompatible.
Conclusion: There is potential for use of these nanoparticles for biomedical application. 
Future work includes in vivo investigation of the targeting capability and effectiveness of these 
nanoparticles in the treatment of lung cancer.
Keywords: superparamagnetic iron oxide nanoparticles, triblock copolymer, doxorubicin 
encapsulation, water uptake, drug encapsulation efficiency
Introduction
Magnetic nanoparticles are a major class of nanoscale materials with the potential 
to revolutionize current clinical diagnostic and therapeutic techniques. Due to their 
unique physical properties and ability to function at the cellular and molecular level 
of biological interactions, magnetic nanoparticles are being actively investigated as 
the next generation of magnetic resonance imaging contrast agents1 and as carriers for 
targeted drug delivery.2,3 Although early research in the field can be dated back several 
decades, a recent surge of interest in nanotechnology has significantly expanded the 
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breadth and depth of magnetic nanoparticle research. With a 
wide range of applications in the detection, diagnosis, treat-
ment of illnesses such as cancer,4 cardiovascular disease,5 and 
neurological disease,6 magnetic nanoparticles may soon play 
a significant role in meeting tomorrow’s health care needs.
As therapeutic tools, magnetic nanoparticles have been 
evaluated extensively for targeted delivery of pharmaceuticals 
through magnetic drug targeting7,8 and by active targeting 
through the attachment of high affinity ligands.9–11 With the 
ability to utilize magnetic attraction or specific targeting of 
disease biomarkers, magnetic nanoparticles offer an attractive 
means of remotely directing therapeutic agents specifically to 
a disease site, while simultaneously reducing dosage and the 
deleterious side effects associated with nonspecific uptake of 
cytotoxic drugs by healthy tissue. Also referred to as magnetic 
targeted carriers, colloidal iron oxide particles in early clini-
cal trials have demonstrated some degree of success with the 
technique and shown satisfactory toleration by patients.12,13 
Although not yet capable of reaching levels of safety and 
efficacy for regulatory approval, preclinical studies indicate 
that some of the shortcomings of magnetic drug targeting 
technology, such as poor penetration depth and diffusion 
of the released drug from the disease site, can be overcome 
by improvements in magnetic targeted carrier design.14,15 
  Furthermore, use of magnetic nanoparticles as carriers in mul-
tifunctional nanoplatforms as a means of real-time monitoring 
of drug delivery is an area of intense interest.16,17
A significant challenge associated with the application of 
these magnetic nanoparticle systems is their behavior in vivo. 
The efficacy of many such systems is often compromised 
due to recognition and clearance by the reticuloendothelial 
system prior to reaching the target tissue, as well as by an 
inability to overcome biological barriers, such as the vascular 
endothelium or the blood–brain barrier. The fate of these 
magnetic nanoparticles upon intravenous administration 
is highly dependent on their size, morphology, charge, and 
surface chemistry. These physicochemical properties of 
nanoparticles directly affect their subsequent pharmacoki-
netics and biodistribution.18 To increase the effectiveness 
of magnetic nanoparticles, several techniques, including 
reducing size and grafting nonfouling polymers, have been 
employed to improve their “stealthiness” and increase their 
blood circulation time to maximize the likelihood of reaching 
targeted tissues.19,20
The major disadvantage of most chemotherapeutic 
approaches to cancer treatment is that most of them are 
nonspecific. Therapeutic (generally cytotoxic) drugs are 
  administered intravenously, leading to general systemic 
distribution (Figure 1). The nonspecific nature of this 
technique results in the well known side effects of chemo-
therapy because the cytotoxic drug attacks normal healthy 
cells in addition to its primary target and tumor cells.21,22 
Magnetic nanoparticles can be used to overcome this great 
disadvantage. Nanoparticles can be used to treat tumors in 
three different ways: specific antibodies can be conjugated 
to the magnetic nanoparticles to bind selectively to related 
receptors and inhibit tumor growth; targeted magnetic nano-
particles can be used via hyperthermia for tumor therapy; 
and drugs can be loaded onto the magnetic nanoparticles 
for targeted therapy.23–25 The targeted delivery of antitumor 
agents adsorbed on the surface of magnetic nanoparticles is 
a promising alternative to conventional chemotherapy. The 
particles loaded with the drug are concentrated at the target 
site with the aid of an external magnet. The drugs are then 
released at the desired area.26 Magnetic particles smaller than 
4 µm are eliminated by cells of the reticuloendothelial sys-
tem, mainly in the liver (60%–90%) and spleen (3%–10%). 
Particles larger than 200 nm are usually filtered to the spleen, 
the cutoff point of which extends up to 250 nm. Particles up 
to 100 nm are mainly phagocytosed via liver cells. In general, 
the larger the particles, the shorter their plasma half-life.27
Functionalization of magnetic nanoparticles with amino 
groups, silica, polymers, various surfactants, or other 
organic compounds is usually done in order to achieve 
  better physicochemical properties. Moreover, the core/shell 
structures of magnetic nanoparticles have the advantages 
Systemic drug deliveryM agnetic targeting
Figure 1 Concept of magnetic drug targeting.20
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of good dispersion, high stability against oxidation, and an 
appreciable amount of drug can be loaded into the polymer 
shell. Furthermore, lots of functional groups from polymers 
on the surface can be used for further functionalization to 
obtain various properties.28 It is preferable that magnetic 
nanoparticles retain sufficient hydrophilicity with coating, 
and do not exceed 100 nm in size in order to avoid rapid 
clearance by the reticuloendothelial system.29 It was found 
that surface functionalization also plays a key role in nano-
particle toxicity.30
Poly (L-lactic acid) (PLLA) and its copolymers with 
glycolic acid, poly (D,L-lactic-co-glycolic acid) (PLGA) 
have been extensively used as biodegradable carriers for drug 
delivery31,32 and as temporal scaffolds for tissue engineer-
ing.33,34 These biodegradable aliphatic polyesters with proven 
biocompatibility have versatile biodegradation properties 
depending on their molecular weight and chemical compo-
sitions.35 Nevertheless, there have been many attempts to 
improve the properties of the copolymer to make them suit-
able for a specific application. For example, to prolong the 
circulation time of PLGA nanoparticles in the blood stream 
in vivo, PLLA:poly(ethylene glycol) (PEG) triblock copo-
lymers were coated onto the surface of PLGA nanoparticles 
by simple blending of PLLA-PEG triblock copolymers with 
PLGA during the nanoparticle formulation process.36
The aim of the present work was to assess the merits of 
Fe3O4-PLGA-PEG nanoparticles as anticancer drug carriers. 
For this purpose, magnetic Fe3O4 nanoparticles were first pre-
pared and then the copolymer PLGA-PEG was synthesized 
with PEG of various molecular weights (Figure 2).
Copolymer was confirmed with  1H nuclear magnetic 
resonance (NMR), differential scanning calorimetry (DSC), 
and Fourier transform infrared (FTIR) spectra. Molecular 
weight was determined by gel permeation chromatography. 
  Doxorubicin was chosen for the encapsulation studies in nano-
particles made of Fe3O4-PLGA-PEG due to its well known 
physicochemical properties and low cost.37,38   Doxorubicin 
was encapsulated within nanoparticles made of Fe3O4-
PLGA-PEG using the double emulsion method (w/o/w). The 
nanoparticles were characterized in terms of size, in vitro 
cytotoxicity, and in vitro release of doxorubicin.39
Materials and methods
Materials
Ferric chloride hexahydrate (FeCl3 ⋅ 6H2O), ferrous   chloride 
tetrahydrate (FeCl2 ⋅ 4H2O), and ammonium hydroxide 
(25 wt%) were purchased from Fluka (Buchs, Switzerland). 
D, L-lactide and glycolide were purchased from Sigma-Aldrich 
(St Louis, MO) and recrystallized with ethyl acetate. Stannous 
octoate (Sn (Oct)2:stannous 2-ethylhexanoate), PEG (molecu-
lar weight 2000, 3000, and 4000), and dimethyl sulfoxide 
were purchased from Sigma-Aldrich. PEGs were dehydrated 
under vacuum at 70°C for 12 hours and used without further 
purification. Doxorubicin hydrochloride was purchased from 
Sigma-Aldrich. X-ray diffraction, Rigaku D/MAX-2400 x-ray 
diffractometer with Ni-filtered Cu Kα radiation, and scanning 
electron microscopy (SEM) measurements were conducted 
using VEGA/TESCAN. DSC measurements were conducted 
using the Perkin Elmer 7 series. The drug-loading capacity 
and release behavior were determined using an ultraviolet-
visible 2550spectrometer (Shimadzu, Tokyo, Japan). Infrared 
spectra were recorded in real-time with a Perkin Elmer series 
FTIR. The magnetic property was measured on a vibrating 
sample magnetometer (Meghnatis Daghigh Kavir, Iran) at 
room temperature.  1H NMR spectra was recorded in real-
time with a Brucker DRX 300 spectrometer operating at 
300.13 mHz. The average molecular weight was obtained 
by gel permeation chromatography performed in dichlo-
romethane (CH2Cl2) with a Waters Associates Model ALC/
gel permeation chromatography 244 apparatus. The samples 
were homogenated using a homogenizer (SilentCrusher M, 
Heidolph Instruments GmbH, Schwabach, Germany). The 
organic phase was evaporated by rotary (Rotary Evaporators, 
Heidolph Instruments, Hei-VAP series).
Synthesis of superparamagnetic  
magnetic nanoparticles
Superparamagnetic magnetitc nanoparticles were prepared 
using an improved chemical coprecipitation   method.40 
According to this method, 3.1736 g of FeCl2 ⋅ 4H2O 
(0.016 mol) and 7.5684 g of FeCl3 ⋅ 6H2O (0.028 mol) 
were dissolved in 320 mL of deionized water, such that 
Fe2+/Fe3+ = 1/1.75. The mixed solution was stirred under nitro-
gen at 80°C for 1 hour (Figure 3A). Then, NH3 ⋅ H2O 40 mL 
was injected into the mixture rapidly, stirred under nitrogen 
for another hour, and then cooled to room temperature 
(Figure 3B). The precipitated particles were washed five 
times with hot water and separated by magnetic decantation 
(Figure 3C). Finally, the magnetic nanoparticles were dried 
under vacuum at 70°C.
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Figure 2 Structure of the PEg–PLgA copolymer.
Abbreviations: PEg, poly (ethylene glycol); PLgA, poly (D, L-lactic-co-glycolic acid).
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Preparation of PLgA-PEg triblock copolymer
PLGA-PEG copolymers with different molecular weights 
of PEG (PEG2000, PEG3000, and PEG4000) as an initiator were 
prepared by a melt polymerization process under vacuum 
using stannous octoate [Sn(Oct)2:stannous 2-ethylhexanoate] 
as a catalyst.41 DL-lactide (14.4 g), glycolide (3.86 g), and 
PEG2000 or PEG3000 or PEG4000 8 g (45% w/w) in a bottleneck 
ﬂask were heated to 140°C under a nitrogen atmosphere 
for   complete melting. The molar ratio of DL-lactide and 
glycolide was 3:1. Then 0.05% (w/w) stannous octoate was 
added and the temperature of the reaction mixture was raised 
to 180°C. The temperature was maintained for 4 hours. The 
polymerization was carried out under vacuum. The copoly-
mer was recovered by dissolution in methylene chloride fol-
lowed by precipitation in ice-cold diethyl ether. The synthesis 
process of PLGA-PEG copolymer is shown in Figure 4A. 
A triblock copolymer of PLGA-PEG was prepared by ring 
opening polymerization of DL-lactide and glycolide in the 
presence of PEG2000, PEG3000, and PEG4000 (Figure 4B).42
Measurement of copolymer
The 1H NMR spectra were recorded in CDCl3 on a Bruker 
AM 300.13 mHz spectrometer. The FTIR (Perkin Elmer 
series) spectrum was obtained from a neat film cast of the 
chloroform copolymer solution between KBr tablets. Gel per-
meation chromatography was performed in dichloromethane 
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Figure 4 (A) Preparation of a triblock copolymer of PLgA-PEg, and (B) mechanism of PLgA-PEg prepared by Sn (Oct)2 as catalyst.42
Abbreviations: PEg, poly (ethylene glycol); PLgA, poly (D, L-lactic-co-glycolic acid).
Figure 3 (A) Reactor of synthesis of superparamagnetic magnetite nanoparticles, 
(B)  preparation  of  Fe3O4  magnetite  nanoparticles,  and  (C)  magnetite-hexane 
suspension attached to a magnet.
NH3 H2O
C A
B
Solution of Fe2+
and Fe3+
2 FeCl3 + FeCl2 + 4 H2O + 8 NH3 → Fe3O4 + 8 NH4Cl
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using a Waters Associates (Milford, MA) Model ALC/gel 
permeation chromatography 244 apparatus. The molecular 
weight and molecular weight distribution of the copolymer 
were calculated using polystyrene as the standard. The ther-
mogram characteristics of selected batches of nanoparticles 
were determined by DSC thermogram analysis (Perkin 
Elmer 7 series) on the glass transition temperature or melt-
ing point.
Doxorubicin-loaded Fe3O4 magnetic nanoparticles 
modified with PLGA-PEG copolymers
Doxorubicin-loaded Fe3O4 magnetic nanoparticles modified 
with PLGA-PEG copolymers were prepared using the double 
emulsion method (w/o/w) employed by Song et al43 with 
minor modifications. An aqueous solution of doxorubicin 
5 mg/5 mL was emulsified in 10 mL dichloromethane, in 
which 120 mg of the copolymer and 4 mg magnetic nanopar-
ticles had been dissolved, using a probe homogenizer or soni-
cation at 20,000 rpm for 30 seconds. This w/o emulsion was 
transferred to a 50 mL aqueous solution of polyvinyl alcohol 
1% and the mixture was probe-homogenized (or sonicated) 
at 72,000 rpm for one minute. The w/o/w emulsion formed 
was gently stirred at room temperature until evaporation of 
the organic phase was completed or the organic phase was 
evaporated (Heidolph Instruments). The nanoparticles were 
purified by applying two cycles of centrifugation (12,000 rpm 
for 1 hour in a Biofuge 28 RS, Heraeus centrifuge) and 
reconstituted with deionized and distilled water. The nanopar-
ticles were finally filtered through a 1.2 mm filter (Millipore, 
Bedford, MA). In order to increase doxorubicin entrapment in 
the nanoparticles, the external aqueous phase used during the 
second emulsification step was saturated with doxorubicin. 
Blank nanoparticles were also prepared by the same method 
without adding doxorubicin at any stage of the preparation 
(Figure 5).44
Drug loading and determination  
of doxorubicin entrapment efficiency
Doxorubicin, an anticancer drug, was used for the drug 
loading and release studies. In brief, 20 mg of lyophilized 
nanoparticles and 5 mg of doxorubicin were dispersed in 
phosphate-buffered solution. The solution was stirred at 
4°C for 3 days to allow doxorubicin to entrap within the 
nanoparticle network. This value was then compared with 
the total amount of doxorubicin to determine the doxorubi-
cin loading efficiency of the nanoparticles. The amount of 
nonentrapped doxorubicin in aqueous phase was determined 
using an ultraviolet 2550 (λex 470 nm and λem 585 nm) spec-
trophotometer (Shimadzu). This procedure permits analysis 
of a doxorubicin solution with removal of most interfering 
substances.45 The amount of doxorubicin entrapped within 
the nanoparticles was calculated by the difference between 
the total amount used to prepare the nanoparticles and the 
amount of doxorubicin present in the aqueous phase, using 
the following formula:
Loading efficiency % =   [(amount of loaded drug in mg)
  /(amount of added drug in mg)] × 100%
In vitro drug release kinetics study
To study the drug release profile of the synthesized doxo-
rubicin-loaded Fe3O4 magnetic nanoparticles modified with 
Centrifuge
Redisperse
Characterization
Solvent
evaporation
Ultrasonication
Surfactant
+
Water
Polymer
drug
magnetite
+
Solvent (w/o) hemogenite 30 s →
(w/o/w) hemogenite 60 s →
Figure 5 Process of w/o/w double emulsion method.44
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Figure 6 Cytotoxic effect of Fe3O4-PLgA-PEg4000 on A549 lung cancer cell line 
after 24 hours (A), 48 hours (B), and 72 hours (C) exposure.
Abbreviations: PEg, poly (ethylene glycol); PLgA, poly (D, L-lactic-co-glycolic acid).
PLGA-PEG copolymers, 3 mg of drug-loaded nanoparticles 
were dispersed in 30 mL of phosphate-buffered solution 
(pH 7.4) and acetate buffer (pH 8, the pH value for survey 
pH-dependent and pH sensitivity of drug release kinetics). 
Samples were incubated at various temperatures from 37°C 
to 40°C. At designated time intervals, a 3 mL sample was 
removed and same   volume was reconstituted by adding 3 mL 
of fresh phosphate-buffered solution and acetate buffer to 
each sample. After the experiment, the samples were ana-
lyzed using ultraviolet spectroﬂuorometry to determine the 
amount of doxorubicin released (λex 470 nm and λem 585 nm 
for doxorubicin measurement).46
Cell culture
In vitro cytotoxicity and cell culture study
An A549 lung cancer cell line (kindly donated by the 
Pharmaceutical Nanotechnology Research Center, Tabriz 
University of Medical Sciences, Tabriz, Iran) was cultured 
in RPMI1640 (Gibco, Invitrogen, Carlsbad, CA) supple-
mented with 10% heat-inactivated fetal bovine serum (Gibco, 
Invitrogen), 2 mg/mL sodium bicarbonate, 0.05 mg/mL 
penicillin G (Serva, Germany), 0.08 mg/mL streptomycin 
(Merck, Germany) and incubated at 37°C with humidified 
air containing 5% CO2. After culturing a sufficient amount 
of cells, the cytotoxic effect of Fe3O4-PLGA-PEG4000 was 
studied using 24-hour, 48-hour, and 72-hour MTT assays.47 
Brieﬂy, 1000 cells/well were cultivated in a 96-well plate. 
After 24 hours of incubation at 37°C in a humidified atmo-
sphere containing 5% CO2, the cells were treated with serial 
concentrations of Fe3O4-PLGA-PEG4000-doxorubicin (0 mg/
mL to 0.57 mg/mL) for 24, 48, and 72 hours in a quadrupli-
cate manner, while cells treated with 0 mg/mL extract and 
200 µL culture medium containing 10% dimethylsulfoxide 
served as a control (Figure 6). After incubation, the medium 
in all wells of the plate was replaced with fresh medium and 
the cells were left for 24 hours in an incubator. The medium 
in all the wells was then removed carefully, and 50 µL of 
2 mg/mL MTT (Sigma-Aldrich) dissolved in phosphate-
buffered solution was added to each well, and the plate was 
covered with aluminum foil and incubated for 4.5 hours. 
After removing the contents of the wells, 200 µL of pure dim-
ethylsulfoxide was added to the wells. Sorensen’s glycine buf-
fer 25 µL was then added and the absorbance of each well was 
immediately read at 570 nm using an EL × 800 microplate 
absorbance reader (Bio-Tek Instruments, Winooski, VT) with 
a reference wavelength of 630 nm.48
Cell treatment
After determination of IC50, 1 × 106 cells were treated with 
serial concentrations of Fe3O4-PLGA-PEG4000-doxorubicin 
(0.028, 0.057, 0.114, 0.142, 0.171, and 0.199 mg/mL). For 
the control cells, the same volume of 10% dimethylsulfoxide 
without Fe3O4-PLGA-PEG4000-doxorubicin was added to 
the ﬂask containing control cells. The culture ﬂasks were 
then incubated at 37°C containing 5% CO2 using a humidi-
fied atmosphere incubator for a 24-hour exposure duration 
(Figure 7).
Nanoparticle characterization
Power x-ray diffraction (Rigaku D/MAX-2400 x-ray diffrac-
tometer with Ni-filtered Cu Kα radiation) was used to inves-
tigate the crystal structure of the magnetic nanoparticles. 
The size and shape of the nanoparticles was determined 
by SEM. The sample was dispersed in ethanol and a small 
drop was spread onto a 400 mesh copper grid. The thermo-
gram characteristics of selected batches of nanoparticles 
were determined by DSC thermogram analysis (Perkin 
Elmer 7 series) on the glass transition temperature or melt-
ing point. The magnetization curves of the samples were 
measured using vibrating sample magnetometry at room 
temperature. The infrared spectra were recorded by a FTIR 
spectrophotometer (Perkin Elmer series), and the sample and 
KBr were pressed to form a tablet. 1H NMR spectra were 
recorded in real-time with a Brucker DRX 300 spectrometer 
operating at 300.13 mHz.
X-ray diffraction patterns
Figure 8 shows the x-ray diffraction patterns for pure Fe3O4 
and doxorubicin-loaded Fe3O4 magnetic nanoparticles modi-
fied with PLGA-PEG copolymers. It is apparent that the dif-
fraction pattern for our Fe3O4 nanoparticles is close to the 
standard pattern for crystalline magnetite. The characteristic 
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diffraction peaks are marked, respectively, by their indices 
(220), (311), (400), (422), (511), and (440), which could be 
well indexed to the inverse cubic spinel structure of Fe3O4 
(JCPDS card 85–1436). Characteristic diffraction peaks 
were also observed for doxorubicin-loaded Fe3O4 magnetic 
nanoparticles modified with PLGA-PEG copolymers. This 
demonstrates that modification of the Fe3O4 nanoparticles did 
not lead to any crystal phase change. The average crystallite 
size D was about 15 nm and obtained from the Sherrer equa-
tion D = Kλ/(β cos θ), where K is the constant, λ is the x-ray 
wavelength, and β is the peak width of half-maximum.49
Size and size distribution
The surface morphology of the nanospheres during the 
incubation period was observed by SEM. The nanographs 
of pure Fe3O4 nanoparticles (Figure 9A), PLGA-PEG copo-
lymers (Figure 9B), and doxorubicin-loaded Fe3O4 mag-
netic nanoparticles modified with PLGA-PEG copolymers 
(Figure 9C) are shown. Observing the photograph, it can 
be seen that the nanoparticles were well aggregated, which 
was due to the nanosize of the Fe3O4 of about 20 nm. After 
encapsulation and modification of the doxorubicin-loaded 
Fe3O4 magnetic nanoparticles with PLGA-PEG copolymers, 
the size of the particles changed to 25–75 nm and dispersion 
of the particles was greatly improved (Figure 9B and C), 
which can be explained by the electrostatic repulsion force 
and steric hindrance between the copolymer chains on the 
encapsulated Fe3O4 nanoparticles. The samples were coated 
with gold particles.50
DSC analysis
The thermogram characteristics of selected batches of nano-
particles determined by DSC thermogram analysis (Perkin 
Elmer 7 series) of glass transition temperature or melting 
point is shown (Figure 10). All the samples were placed in an 
aluminum pan and scanned from 35°C to 250°C with a heat-
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Figure 8 X-ray diffraction patterns of pure Fe3O4 nanoparticles.
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Figure 9 Scanning electron microscopy of (A) Fe3O4 magnetic nanoparticles, (B) PLgA-PEg nanoparticles, and (C) doxorubicin-loaded Fe3O4 magnetic nanoparticles 
modified with PLGA-PEG copolymers.
Abbreviations: PEg, poly (ethylene glycol); PLgA, poly (D, L-lactic-co-glycolic acid).
ing rate of 20°C per minute. All the DSC thermograms were 
obtained from the first heating cycle. Nitrogen was used as a 
sweeping gas. Samples (8 mg) were equilibrated at 250°C and 
purged with pure dry nitrogen at a ﬂow rate of 40 mL/minute. 
The nitrogen was heated to 120°C at 20°C per minute, after 
which it was held isothermally for 3 minutes. The samples 
were cooled back to 200°C at the same rate. After 5 minutes 
at the isothermal stage, the second heating cycle proceeded 
at a 5°C per minute temperature ramp speed to 120°C. 
The glass transition temperature of the polymer was obtained 
by taking the midpoint of the slope during glass transition. 
In the present research, two heating cycles were conducted. 
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Indium was used as the standard reference material to calibrate 
the temperature and energy scales of the DSC   instrument. As 
a control, the pure material was analyzed to observe changes 
in melting point or glass transition temperature.51
Magnetism test
The magnetic properties of the nanoparticles were analyzed 
by vibrating sample magnetometry at room temperature.52 
  Figure 11 shows the hysteresis loops of the samples. The 
saturation magnetization was found to be 17.5 emu/g for 
doxorubicin-loaded Fe3O4 magnetic nanoparticles modified 
with PLGA-PEG copolymers, ie, less than for the pure Fe3O4 
nanoparticles (70.9 emu/g). This difference suggests that a 
large amount of polymer encapsulated the Fe3O4 nanoparticles 
and doxorubicin. With the large saturation magnetization, the 
doxorubicin-loaded Fe3O4 magnetic nanoparticles modified 
with PLGA-PEG copolymers could be separated from the 
reaction medium rapidly and easily in a magnetic field. 
In   addition, there was no hysteresis in the magnetization, 
with both remanence and coercivity being zero, suggesting 
that these magnetic nanoparticles are superparamagnetic. 
When the external magnetic field was removed, the magnetic 
nanoparticles could be well dispersed by gentle shaking. 
These magnetic properties are critical for application in the 
biomedical and bioengineering fields.
Results
Measurement and characterization  
of nanoparticles
FTIR spectroscopy
The F-IR spectrum is consistent with the structure of the 
expected copolymer. FTIR spectroscopy was used to show 
the structure of Fe3O4 and PLGA-PEG copolymer nano-
particles. From the infrared spectra shown in Figure 12A, 
the absorption peaks at 580 cm−1 belonged to the stretching 
vibration mode of Fe–O bonds in Fe3O4 (Table 1). Figure 12B 
−8000
−80
−60
−40
−20
0
20
40
60
80
Fe3O4
Fe3O4-PLGA-PEG-DOX
M
a
g
n
e
t
i
z
a
t
i
o
n
 
(
e
m
u
/
g
)
Applied field (Oe)
8000 6000 4000 2000 0 −2000 −4000 −6000
Figure 11 Magnetic behavior of magnetic nanoparticles.
Abbreviations:  PLgA-PEg-DOX,  Doxorubicin-loaded  poly(lactide-co-glcolide)-
polyethylene glycol.
8.768 20 40 60 80 100 120 1401 60 1802 00 220 2402 54.5
Temperature (°C)
60.64
55
50
45
40
30
25
20
15
10.75
 
H
e
a
t
 
F
l
o
w
 
E
n
d
o
 
D
o
w
n
 
(
m
W
)
336.9
300
250
200
150
100
50
0
-36.58
35
D
e
r
i
v
a
t
i
v
e
H
e
a
t
F
l
o
w
(
m
W
/
m
i
n
)
Figure 10 Thermogram characteristics of selected batches of nanoparticles.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
519
Doxorubicin-loaded Fe3O4 magnetic nanoparticlesInternational Journal of Nanomedicine 2012:7
shows that absorption band at 3509.9 cm−1 is assigned to 
terminal hydroxyl groups in the copolymer from which PEG 
homopolymer has been removed. The bands at 3010 cm−1 
and 2955 cm−1 are due to C–H stretch of CH, and 2885 cm−1 
due to C–H stretch of CH. A strong band at 1762.6 cm−1 is 
assigned to C=O stretch.   Absorption at 1186–1089.6 cm−1 
is due to C–O stretch.53
1H NMR spectrum of PEg-PLgA copolymer
The basic chemical structure of PEG-PLGA copolymer 
is confirmed by  1H NMR spectra that were recorded in 
  real-time with a Brucker DRX 300 spectrometer operating 
at 400 mHz. Chemical shift (δ) was measured in ppm using 
tetramethylsilane as an internal reference (Figure 13). One of 
the striking features is a large peak at 3.65 ppm, correspond-
ing to the methylene groups of PEG. Overlapping doublets at 
1.55 ppm are attributed to the methyl groups of the D-lactic 
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Table 1 Fourier transform infrared spectrum for Fe3O4
84
System Infrared bands (cm-1) Description
Fe3O4 440 Absorption band of Fe–O
580 Absorption band of Fe–O
620 Absorption band of Fe–O
3402 –OH vibrations
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acid and L-lactic acid repeat units. The multiples at 5.2 and 
4.8 ppm correspond to the lactic acid CH and the glycolic 
acid CH, respectively, with the high complexity of the two 
peaks resulting from different D-lactic, L-lactic, and glycolic 
acid sequences in the polymer backbone.54
gel permeation chromatogram  
of PEg-PLgA copolymer
Molecular weights and molecular weight distribution of the 
obtained copolymer are determined by means of gel permeation 
chromatography gel permeation chromatography (Figure 14). 
The average molecular weight is 16,400. The unimodal mass 
distribution excluded the presence of PEG4000 or PLGA55 
(molecular weight 16,400, number averaged molecular 
weight 7131, z-average molecular weight, 20,300, molecular 
weight at peak top 6850).
Physicochemical characterization  
of nanoparticles
In order to investigate the physicochemical characteriza-
tion of nanoparticles prepared by the double emulsion 
method (w/o/w), the nanoparticles were observed by SEM 
(Figure 9). From these micrographs, nanoparticles prepared 
with PLGA-PEG2000, PLGA-PEG3000, and PLGA-PEG4000 
containing doxorubicin were spherical in shape and uniform, 
with a size range of about 30–60 nm. The encapsulation 
efficiency values achieved for doxorubicin were inﬂuenced 
by the presence of PEG of different molecular weights in 
the PLGA chains (Table 2). Compared with PLGA-PEG4000 
nanoparticles (78%), PLGA-PEG3000 and PLGA-PEG2000 
nanoparticles showed a lower encapsulation efficiency of 
73% and 69.5%, respectively. The zeta potential values were 
obviously affected by the presence of different molecular 
weight PEG chains. Higher negative values were obtained for 
PLGA-PEG2000 nanoparticles (−33.2 mV). A marked decrease 
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PEG groups and formation of positively charged chains in 
the polymer structure.
In vitro cytotoxicity study
The MTT assay is an important method for evaluating the 
in vitro cytotoxicity of biomaterials. In the MTT assay, 
absorbance has a significant linear relationship with cell 
numbers. Corresponding optical images of cells are shown 
in Figure 15. In the current work, the MTT assay showed 
that Fe3O4-PLGA-PEG2000-doxorubicin has dose-dependent 
and time-dependent cytotoxicity against the A549 lung can-
cer cell line (IC50 0.13–0.26 mg/mL). Also, the MTT assay 
showed that Fe3O4-PLGA-PEG3000-doxorubicin has dose-
dependent and time-dependent cytotoxicity against the A549 
lung cancer cell line (IC50 0.08 mg/mL), that Fe3O4-PLGA-
PEG4000-doxorubicin has no dose-dependent cytotoxicity 
but does have time-dependent cytotoxicity against the A549 
lung cancer cell line (IC50 0.17–0.48 mg/mL), and that pure 
doxorubicin has dose-dependent but not time-dependent 
cytotoxicity against this cell line (IC50 0.15–0.16 mg/mL). 
Therefore, there is a need for further study of doxorubicin-
loaded Fe3O4 magnetic nanoparticles modified with PLGA-
PEG copolymers using the A549 lung cancer cell line in the 
future. However, the results of the current work demonstrate 
that the IC50 values for Fe3O4-PLGA-PEG4000-doxorubicin, 
Fe3O4-PLGA–PEG3000-doxorubicin, Fe3O4-PLGA-PEG2000-
doxorubicin, and pure doxorubicin are about 0.18 mg/mL, 
0.08 mg/ml , 0.13 mg/mL, and 0.15 mg/mL, respectively, 
in this cell line.
Discussion
To reduce or minimize undesired interactions or undesired 
uptake into normal sites, a biodegradable nanocarrier has 
been developed for doxorubicin, wherein the amount and site 
of drug release is controlled by the structure of copolymer-
coated magnetic nanoparticles and pH. This nanoparticle 
was designed and prepared so that the carrier can be used 
for targeting a broad range of solid tumors. For this purpose, 
AB triblock copolymers of PLGA-PEG were synthesized by 
Table 2 Physicochemical characterization and encapsulation efficiency of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified 
with PLgA-PEg2000, PLgA-PEg3000, and PLgA-PEg4000
Fe3O4 copolymer Size (nm) Zeta potential (mV) Encapsulation efficiency (%)
Fe3O4-PLgA-PEg2000 50 ± 15 −33.2 ± 0.9 69.5%
Fe3O4-PLgA-PEg3000 35 ± 13 −22.5 ± 0.7 73%
Fe3O4-PLgA-PEg4000 29 ± 11 −17.4 ± 0.5 78%
Note: Mean ± standard deviation (n = 3).
Abbreviations: PEg, poly (ethylene glycol); PLgA, poly (D, L-lactic-co-glycolic acid).
in the surface charge for PLGA-PEG4000 nanoparticles 
(−17.4 mV) occurred.56
In vitro release experiment
The in vitro doxorubicin release profiles were obtained by 
representing the percentage of doxorubicin release with 
respect to the amount of doxorubicin encapsulated. For 
three nanoparticles, doxorubicin release occurred in two 
phases: an initial burst release, with a significant amount 
of drug released within 12 hours, 30.1% for Fe3O4 magnetic 
nanoparticles modified with PLGA-PEG4000 nanoparticles, 
25.6% for Fe3O4 magnetic nanoparticles modified with 
PLGA-PEG3000, and 20.7% for Fe3O4 magnetic nanopar-
ticles modified with PLGA-PEG2000 nanoparticles; and 
after 12 hours, the doxorubicin release profiles showed a 
sustained release pattern. The cumulative amount of doxo-
rubicin release over 2 days was 83.4% from Fe3O4-PLGA-
PEG4000, 70% from Fe3O4-PLGA-PEG3000, and 60.8% from 
Fe3O4- PLGA-PEG2000 nanoparticles.57 The doxorubicin 
release rate from the Fe3O4-PLGA-PEG nanoparticles was 
also pH-dependent and enhanced at pH 5.8. It is gener-
ally assumed that a drug is released by several processes, 
including diffusion through the polymer matrix, release 
by polymer degradation, and solubilization and diffusion 
through microchannels that exist in the polymer matrix or 
are formed by erosion. The magnetic-coated copolymers 
prepared in the present work are AB triblock copolymers 
composed of hydrophobic A blocks (lactide-co-glycolide) 
and hydrophilic B blocks (central PEG). These copoly-
mers are not soluble in water, but exhibit reverse thermal 
and pH-dependent gelation properties. Hydrolysis of the 
ester linkage in these polymers will cause the swelling 
to increase with time as hydrolysis proceeds. The gel 
becomes increasingly pH-sensitive as hydrolysis proceeds, 
and carboxylic acid groups are generated in the structure. 
Within about 6 days, we can consider that drug is released 
from the Fe3O4-PLGA-PEG nanoparticles by a diffusion 
mechanism in vitro. The swelling of the particles increases 
in acidic buffered solutions due to protonation of central 
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Figure 15 Morphological effect of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with PLGA-PEG copolymers on A549 lung cancer cell line after 24 hours of 
treatment. (A) Control cells, (B) doxorubicin-loaded Fe3O4-PLgA-PEg2000-Doxorubicin, (C) Fe3O4-PLgA-PEg3000-doxorubicin, (D) Fe3O4-PLgA-PEg4000-doxorubicin, and 
(E) pure doxorubicin. 
Abbreviations: PEg, poly (ethylene glycol); PLgA, poly (D, L-lactic-co-glycolic acid).
ring opening polymerization of lactide and glycolide in the 
presence of PEG2000, PEG3000, and PEG4000.58–62 The 1H-NMR 
and FTIR spectra were consistent with the structure of the 
PLGA-PEG copolymer. The molecular weight was deter-
mined by gel permeation chromatography. In this work, 
doxorubicin-loaded Fe3O4 magnetic nanoparticles modified 
with PLGA-PEG copolymers were obtained by encapsulation 
of doxorubicin in the nanoparticles.63–67 For this purpose, the 
double emulsion (w/o/w) technique was considered the most 
appropriate method. However, the inﬂuence of other factors 
on entrapment efficiency using this technique is very com-
plicated, and includes copolymer concentration in organic 
solution, volume of the inner aqueous phase, volume of the 
outer aqueous phase, doxorubicin concentration in the inner 
aqueous phase, the first homogenized speed and time, the 
second homogenized speed and time, and polyvinyl alcohol 
concentration.68,69 The loading efficiency values achieved 
for doxorubicin were different between the various Fe3O4-
PLGA-PEG nanoparticles, which could be attributable to 
the presence of different molecular weights of PEG in the 
PLGA chains, but the mechanism is indistinct. Compared 
with Fe3O4-PLGA-PEG4000 nanoparticles, Fe3O4-PLGA-
PEG3000, and Fe3O4-PLGA-PEG2000 nanoparticles showed a 
marked decrease in encapsulation efficiency. The entrapment 
efficiency was 78%, 73%, and 69.5%, and the particle size 
was about 25–75 nm.
The results demonstrated in vitro that the doxorubicin-
loaded Fe3O4-PLGA-PEG nanoparticles show pH sensitivity 
and can be applied for targeting extracellular pH, and could 
be an effective carrier for anticancer drugs. It is expected that 
at tumor pH, the doxorubicin-loaded nanoparticles made of 
Fe3O4-PLGA-PEG can show enhanced cytotoxicity compared 
with that at normal pH.70–74
In this paper, higher and faster doxorubicin release 
was observed for Fe3O4-PLGA-PEG4000 nanoparticles 
than for Fe3O4-PLGA-PEG3000 and Fe3O4-PLGA-PEG2000 
at 12 hours. This difference could be to the presence of 
PEG4000 in the PLGA chains. In conclusion, modification 
of the magnetic nanoparticles could have potential benefit 
for drug delivery. Our results show that magnetic Fe3O4 
PLGA-PEG   nanoparticles could be an effective carrier for 
drug delivery.75–79 The in vitro cytotoxicity test showed that 
the Fe3O4-PLGA:PEG4000 magnetic nanoparticles had no 
cytotoxicity and were biocompatible, which means there 
is potential for biomedical application.80 Also, the IC50 of 
doxorubicin-loaded Fe3O4 magnetic nanoparticles modified 
with PLGA-PEG copolymers on an A549 lung cancer cell 
line was time-dependent.
Conclusion
Superparamagnetic iron oxide nanoparticles were prepared 
using an improved chemical coprecipitation method and 
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then PLGA-PEG copolymer was used to encapsulate Fe3O4 
nanoparticles by an emulsion method (w/o/w). The results 
indicate that the copolymer chains effectively encapsulated 
the Fe3O4 nanoparticles. Saturation magnetization was found 
to be 17.5 emu/g. These particles were employed in encapsula-
tion of doxorubicin under mild conditions and could be used 
in drug delivery. An in vitro cytotoxicity study demonstrated 
that the PLGA-PEG nanoparticles and Fe3O4-PLGA-PEG 
nanoparticles had no cytotoxicity and were biocompatible. 
Our results suggest that supercritical ﬂuid technology is a 
promising technique to produce drug-polymer magnetic 
composite nanoparticles for the design of controlled-release 
drug systems. Current work demonstrates that doxorubicin-
loaded Fe3O4 magnetic nanoparticles   modified with 
PLGA-PEG triblock copolymers have potent   time-dependent 
antigrowth effects in an A549 lung cancer cell line. Therefore, 
these nanoparticles could become a potent chemopreventive 
and chemotherapeutic system for lung cancer patients and 
constituents of this nanoparticles could be appropriate can-
didates for drug development. Future work will include an in 
vivo investigation of the targeting capability and effectiveness 
of these nanoparticles in the treatment of lung cancer.81,82
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